Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 6, 2009, Pages 1003-1008

  de Oliveira, Larissa ^a   dos S Spiazzi, Cecília Marly ^a   Bortolin, Thaize ^a   Canever, Leila ^a   Petronilho, Fabricia ^a   Gonçalves Mina, Franciele ^a   Dal Pizzol, Felipe ^a   Quevedo, João ^a   Zugno, Alexandra I ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Free radicals; Ketamine; Oxidative stress; Schizophrenia

Indexed keywords

CATALASE; KETAMINE; LIPID; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; LIPID PEROXIDATION; MALE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; RAT; SCHIZOPHRENIA; SINGLE DRUG DOSE;

ANESTHETICS, DISSOCIATIVE; ANIMALS; BRAIN; CATALASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; KETAMINE; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE;

EID: 67651102642     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.05.010     Document Type: Article

References (37)

1. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156 (1999) 1646-1649
2. Aebi H. Catalase, in vitro. Methods Enzymol 105 (1984) 121-126
3. Aksenov M.Y., and Markesbery W.R. Change in thiol content and expression of glutathione redox system gene in the hippocampus and cerebellum in Alzheimer's disease. Neurosci Lett 302 (2001) 141-145
4. Arvindakshan M., Sitasawa S., Debsikdar V., Ghate M., Evans D., Horrobin D.F., et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 53 (2003) 56-64
5. Bowie C.R., and Harvey P.D. Schizophrenia from neuropsychiatry perspective. Mt Sinai J Med 73 (2006) 993-998
6. Bressan R.A., and Pilowskv L.S. Hipótese glutamatérgica da esquizofrenia. Rev Bras Psiquiatr 25 (2003) 177-183
7. Butterfield D.A., and Kanski J. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 122 (2001) 945-962
8. Dietrich-Muszalska A., and Olas B. Modifications of blood platelet proteins of patients with schizophrenia. Platelets 20 (2009) 90-96
9. Dietrich-Muszalska A., Olas B., Głowacki R., and Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology 59 (2009) 1-7
10. Fendri C., Mechri A., Khiari G., Othman A., Kerkeni A., and Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale 32 (2006) 244-252
11. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158 (2001) 1367-1377
12. Halliwell B. Role of free radicals in the neurodegenerative diseases. Therapeutic implications for antioxidant treatment. Drugs Aging 18 (2001) 685-716
13. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J Neurochem 97 (2006) 1634-1658
14. Hunt M.J., Raynaud B., and Garcia R. Ketamine dose-dependently induces high-frequency oscillations in the nucleus accumbens in freely moving rats. Biol Psychiatry 60 (2006) 1206-1214
15. Keilhoff G., Becker A., Grecksch G., Wolf G., and Bernstein H.G. Repeated application of ketamine to rats induces changes in the hippocampal expression of parvalbumin, neuronal nitric oxide synthase and cFOS similar to those found in human schizophrenia. Neuroscience 126 (2004) 591-598
16. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
17. Lipska B.K., and Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Europsychopharmacology 23 (2000) 223-239
18. Lohr J.B., and Browning J.A. Free radical involvement in neuropsychiatry illnesses. J Psychopharmacol Bull 31 (1995) 159-165
19. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-267
20. Mahadik S.P., and Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 10 (1996) 1-17
21. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., and Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol Psychiatry 43 (1998) 674-679
22. Marklund S.L. Pyrogallol autoxidation. In: Greenwald R.A. (Ed). Handbook for oxygen radical research (1985), CRC Press, Boca Raton 243-247
23. Meinsenzahl E.M., Schmitt G.J., Scheuerecker J., and Möller H.J. The role of dopamine for the pathophysiology of schizophrenia. Int Rev Psychiatry 19 (2007) 337-345
24. Ng F., Berk M., Dean O., and Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 11 (2008) 851-876
25. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95 (1979) 351-358
26. Petronijevic N.D., Micic D.V., Duricic B., Marinkovic D., and Paunovic V.R. Substrate kinetics of erythrocyte membrane Na, K-ATPase and lipid peroxides in schizophrenia. Prog Neuro-psychopharmacology Biol Psychiatry 27 (2003) 431-440
27. Pietraszek M. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. Pol J Pharmacol 55 (2003) 133-154
28. Reddy R.D., and Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 55 (1996) 33-43
29. Srivastava N., Barthwal M.K., Dalal P.K., Agarwal A.K., Nag D., Srimal R.C., Seth P.K., and Dikshit M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenic patients. Psychopharmacology 158 (2001) 14014-14015
30. Stadtman E.A. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med 9 (1990) 315-325
31. Tandon R., Keshavan M.S., and Nasrallah H.A. Schizophrenia, "just the facts": what we know in 2008 Part 1: overview. Schizophr Res 100 (2008) 4-19
32. Takuma K., Baba A., and Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog Neurobiol 72 (2004) 111-127
33. Treasaden I.H., and Puri B.K. Cerebral spectroscopic and oxidative stress studies in patients with schizophrenia who have dangerously violently offended. BMC Psychiatry 17 8 Suppl 1 (2008) S7
34. Tsai G., and Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42 (2002) 165-179
35. Yao J.K., Peddy R., Mcelhinny L.G., and Van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr Res 32 (1998) 1-8
36. Young J., McKinney S.B., Ross B.M., Wahle K.W., and Boyle S.P. Biomarkers of oxidative stress in schizophrenic and control subjects. Prostaglandins Leukot Essent Fat Acids 76 (2007) 73-85
37. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 81 (2006) 291-300